Dr Oleg Gluz speaks to ecancer at ESMO 2024 about results from the WSG-TP-II trial. This trial evaluated endocrine therapy plus trastuzumab and pertuzumab versus de-escalated chemotherapy plus trastuzumab and pertuzumab in hormone receptor positive HR and HER2 positive early breast cancer.

207 patients were randomised 1:1 between the two arms and the primary endpoint was pathological complete response.

Dr Gluz reports that the endocrine therapy arm showed excellent survival outcomes and leads to an oportunity for the safe de-escalation of chemotherapy in early HR and HER2 positive early breast cancer.